In an unprecedented move to fortify the safeguard of American genetic data, the Trump administration has clamped down on a critical loophole that previously permitted the export of sensitive genetic material to adversarial nations, most notably China. As of April, a new rule has been enforced to staunch the flow of such critical biological resources, […]
Tag: trials
Avacta Group Revenue and Therapeutics Update
Avacta Group reported a marginal rise in group revenue to £24.42m, with diagnostics division sales increasing by 14.7%. However, therapeutics revenue fell to £0.11m due to the absence of milestones from AffyXell. Avacta continues to expand its clinical and research activities, advancing its lead preCISION programme AVA6000 into phase 1b trials across multiple cancers. The […]
Innovative Bispecific Antibodies by Aptevo Therapeutics
Aptevo Therapeutics, a biotech company, is at the forefront of developing five bispecific antibodies designed for both blood and solid tumors. Currently, two of these antibodies are undergoing clinical trials, while the remaining three are in the preclinical stages. This innovative approach holds great promise in the field of therapeutics, offering potential new treatment options […]
Mipletamig Shows Promise in AML Treatment
In the rapidly evolving field of biotechnology, Aptevo Therapeutics is making waves with its cutting-edge work on Mipletamig. The clinical-stage biotech company has recently revealed promising clinical data from its ongoing Phase 1b/2 RAINIER trial. The trial evaluates Mipletamig, a first-in-class CD123 x CD3 bispecific antibody, in combination with standard-of-care venetoclax and azacitidine (ven/aza). This […]
Role of Remnant Cholesterol in ASCVD
Remnant cholesterol, found in triglyceride-rich lipoproteins, is a key factor in atherosclerotic cardiovascular disease (ASCVD). Dr. Børge G. Nordestgaard discussed its role as an independent risk factor for ASCVD and emerging therapies targeting residual cardiovascular risk beyond LDL cholesterol reduction. With a focus on the evolving understanding of remnant cholesterol and triglyceride-rich lipoproteins (TRLs), Dr. […]
Phage Therapy: Safety, Efficacy, and Future Prospects Review
In today’s biomedical landscape, phage therapy, which utilizes bacteriophages – viruses that infect bacteria – is rapidly emerging as the avant-garde approach to combating bacterial infections. As the world grapples with the escalating threat of antibiotic-resistant bacteria, this innovative therapy is not merely an alternative to antibiotics; it could well be our most potent weapon […]
Early Weight Loss Results of Zealand’s GLP-2 Candidate
In an industry where innovation and breakthroughs are the name of the game, Zealand Pharma’s GLP-2 candidate, dapiglutide, has turned heads with its promising early results in a clinical trial focused on weight loss. Strikingly, the study enrolled an unusually high percentage of male participants – a whopping 95%. This demographic deviation from the norm […]
Zealand Pharma’s Positive Results: 28-Week GLP-1/GLP-2 Trial
Zealand Pharma, a pioneering biotechnology company focused on peptide-based medicines, recently announced compelling results from a 28-week Phase 1b trial involving the innovative GLP-1/GLP-2 receptor dual agonist, dapiglutide. As a dual agonist, dapiglutide represents a significant leap in the realm of obesity treatment, revealing a unique approach to address obesity-related comorbidities driven by low-grade inflammation. […]
Yann Echelard Sells $369K of TG Therapeutics Stock
As a rising star in the biopharmaceutical landscape, TG Therapeutics Inc solidifies its standing as an innovative game-changer in the battle against B-cell diseases. The recent FDA approval of BRIUMVI for managing relapsing multiple sclerosis further underscores the company’s commitment to spearheading the development and commercialization of novel therapies that reshape the treatment paradigm. TG […]
Sensei Biotherapeutics’ Reverse Stock Split Announcement
In a calculated strategy to streamline its common stock structure and meet compliance requirements, Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a Boston-based, clinical-stage biopharmaceutical company, has announced its decision to implement a 1-for-20 reverse stock split. The move, approved by stockholders at the company’s recent annual meeting, is expected to enhance the company’s financial positioning and […]
Dupixent (Dupilumab) Approval for Bullous Pemphigoid Treatment
In a game-changing move for the biotechnology and personalized medicine sector, Regeneron Pharmaceuticals, Inc. has gained approval for Dupixent (dupilumab) as the single targeted treatment for patients with bullous pemphigoid (BP). This marks a significant stride in managing this challenging autoimmune disorder, spotlighting the potential of targeted therapies to revolutionize the treatment landscape. Bullous pemphigoid […]
Unlocking Potential: Recursion Pharmaceuticals’ AI Innovations in Biotech
In the swiftly evolving sphere of biotechnology, trailblazing companies such as Recursion Pharmaceuticals are wielding the might of artificial intelligence (AI) to ignite a paradigm shift in the landscape of drug development. This revolutionary approach has not only turned heads but has also drawn substantial capital investment from industry titans such as Novo Nordisk, who […]
China Emerges as Weight Loss Drug Trial Hub
In the rapidly evolving world of biopharmaceuticals, China has emerged as an unexpected yet strategic battleground for the development and testing of weight loss drugs. Despite its relatively low obesity rate, the nation’s burgeoning population of overweight individuals is fueling a market ripe for obesity interventions, poised to redefine the healthcare landscape in China and […]
Empaveli Shows Leading Efficacy in Rare Kidney Diseases
In a remarkable breakthrough for rare kidney disease treatment, Apellis and Sobi have demonstrated the potential of Empaveli to exhibit ‘best-in-class’ efficacy. This remarkable development represents a significant stride forward in the field, offering a glimmer of hope for patients grappling with these challenging conditions. Concurrently, Otsuka’s sibeprenlimab is making waves in the same sphere […]
Gene Therapy Vectors for Hemophilia: Efficacy and Safety
Recent studies on gene therapy vectors for hemophilia have highlighted the varying effectiveness and risks associated with different AAV isotypes and gene constructs. Dosages ranging from 2 × 10^11 vector genome [vg]/kg to 6 × 10^13 vg/kg have been tested, showing significant reduction in bleeds for both hemophilia A and hemophilia B patients. Phase-1 trials […]
